9 citations · 16 across the 2 of their papers we have counts for
2 papers
stat.ME2022★ 9 cited
Duration of and time to response in oncology clinical trials from the perspective of the estimand framework
Hans-Jochen Weber, Stephen Corson, Jiang Li +6
Duration of response (DOR) and time to response (TTR) are typically evaluated as secondary endpoints in early-stage clinical studies in oncology when efficacy is assessed by the be…
stat.ME2022★ 7 cited
Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions
Kaspar Rufibach, Lynda Grinsted, Jiang Li +3
For the analysis of a time-to-event endpoint in a single-arm or randomized clinical trial it is generally perceived that interpretation of a given estimate of the survival function…